Relation of intraocular concentrations of inflammatory factors and improvement of macular edema after vitrectomy in branch retinal vein occlusion.
OBJECTIVE
To investigate the association of intraocular concentrations of inflammatory factors and improvement of macular edema after vitrectomy for patients with macular edema in branch retinal vein occlusion (BRVO).


METHODS
Retrospective case-control study.


METHODS
Seventeen patients with BRVO who underwent vitreous surgery for macular edema and 15 control patients were enrolled from Hachioji Medical Center of Tokyo Medical University. The concentrations of eight inflammatory factors were measured in vitreous and aqueous fluids obtained at the time of vitrectomy using a flow cytometer. Macular thickness was measured by optical coherence tomography before and one, three, and six months after surgery. Correlations between the concentrations of inflammatory factors and macular thickness were statistically analyzed.


RESULTS
Higher aqueous and vitreous concentrations of vascular endothelial growth factor (VEGF) and interleukin (IL)-8 were significantly correlated with a greater difference in macular thickness between before and six months after surgery (vitreous VEGF, P=.047; aqueous VEGF, P=.032; vitreous IL-8, P=.016; and aqueous IL-8, P=.032). Higher intraocular concentrations of monokine induced by interferon γ (Mig) were significantly correlated with a smaller degree of macular thickness six months after surgery (vitreous Mig, P=.038; aqueous Mig, P=.009).


CONCLUSIONS
High preoperative VEGF, IL-8, and Mig concentrations were associated with improvement of macular edema six months after vitreous surgery in patients with macular edema attributable to BRVO.
Department of Ophthalmology, Hachioji Medical Center of Tokyo Medical University, Tokyo, Japan. yoko-okunuki@nifty.com
Yoko
Y
Okunuki
Yoshihiko
Y
Usui
Naomichi
N
Katai
Takeshi
T
Kezuka
Masaru
M
Takeuchi
Hiroshi
H
Goto
Yoshihiro
Y
Wakabayashi
D000368:Aged; D001082:Aqueous Humor / Q000378:metabolism; D016022:Case-Control Studies; D054370:Chemokine CXCL9 / Q000378:metabolism; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D018836:Inflammation Mediators / Q000378:metabolism*; D016209:Interleukin-8 / Q000378:metabolism; D008266:Macula Lutea / Q000473:pathology; D008269:Macular Edema / Q000378:metabolism / Q000473:pathology / Q000601:surgery*; D008297:Male; D012170:Retinal Vein Occlusion / Q000378:metabolism / Q000473:pathology / Q000601:surgery*; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism; D014821:Vitrectomy; D014822:Vitreous Body / Q000378:metabolism
C080810:CXCL9 protein, human; D054370:Chemokine CXCL9; D018836:Inflammation Mediators; D016209:Interleukin-8; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A